Related Experiment Video
Updated: Jul 13, 2026

Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion
Published on: April 2, 2020
Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis
Thomas R Geiger1, Daniel S Peeper
1Division of Molecular Genetics, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
Abstract:
Anoikis, or cell death induced by cell detachment, provides protection against the metastatic spread of tumor cells. We have previously shown that the neurotrophic receptor tyrosine kinase TrkB suppresses anoikis in rat intestinal epithelial cells and renders them highly tumorigenic and metastatic. Because TrkB is overexpressed in several aggressive human cancers, first attempts are being made to target TrkB in cancer therapy. However, the mechanisms underlying TrkB-mediated anoikis suppression, tumorigenesis, and metastasis still remain largely elusive. Although, to date, most attempts to neutralize TrkB in tumors aim to inactivate its kinase activity, it is unclear whether TrkB kinase activity is required for its oncogenic functions. Indeed, it has been suggested that also other properties of the receptor contribute to functions that are relevant to tumor cell survival. Specifically, several adhesion motifs reside within the extracellular domains of TrkB. In line with this, TrkB-expressing epithelial cells form large cellular aggregates in suspension cultures, possibly facilitating tumor cell survival. Therefore, we set out to study the relative contributions of TrkB's kinase activity and its adhesion domains to anoikis suppression and oncogenicity. On the basis of a structure-function analysis, we report that TrkB kinase activity is required and, unexpectedly, also sufficient for anoikis suppression, tumor formation, and experimental metastasis. Thus, TrkB can act tumorigenically independent of its adhesion motifs. These results suggest that targeting the enzymatic activity of TrkB might be beneficial in cancer therapy.
Insights
Neurotrophic receptor tyrosine kinase TrkB suppresses anoikis, promoting tumor growth and metastasis. Its kinase activity is essential and sufficient for these oncogenic functions, suggesting targeting TrkB
Area of Science:
- Molecular oncology
- Cell biology
- Cancer research
Background:
- Anoikis (cell death upon detachment) is a tumor suppressor mechanism.
- Neurotrophic receptor tyrosine kinase TrkB is overexpressed in aggressive cancers and promotes tumorigenesis and metastasis.
- The precise mechanisms of TrkB-mediated anoikis suppression are not fully understood.
Purpose of the Study:
- To investigate the roles of TrkB's kinase activity and extracellular adhesion domains in anoikis suppression and oncogenicity.
- To determine if TrkB kinase activity is necessary and/or sufficient for TrkB's tumor-promoting functions.
- To elucidate the structure-function relationship of TrkB in cancer progression.
Main Methods:
- Structure-function analysis of TrkB.
- In vitro studies on anoikis suppression in epithelial cells.
- Assessment of tumor formation and experimental metastasis in vivo.
Main Results:
- TrkB kinase activity is required for anoikis suppression, tumor formation, and experimental metastasis.
- TrkB kinase activity alone is sufficient to drive these oncogenic outcomes.
- TrkB's oncogenic functions are independent of its extracellular adhesion motifs.
Conclusions:
- TrkB kinase activity is the critical driver of TrkB-mediated anoikis suppression, tumorigenesis, and metastasis.
- Targeting TrkB's enzymatic activity may be a viable therapeutic strategy for aggressive cancers.
- TrkB's oncogenic potential can be exerted independently of its cell adhesion properties.
Related Concept Videos
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Mitogens and the Cell Cycle
Receptor Tyrosine Kinases